Arrowhead announced that the European Medicines Agency, or EMA, Committee for Orphan Medicinal Products, or COMP, issued a positive opinion on Arrowhead’s application for orphan designation of its RNAi candidate, ARO-AAT, for the treatment of congenital alpha-1 antitrypsin deficiency. ARO-AAT was previously granted orphan drug designation by the FDA in February.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.